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Atrial fibrillation (AF) is the most common arrhythmia in the general population characterized by uncoordinated 
electric activation of the atria.1 Its prevalence increases with 
age ranging from 0.1% among patients <55 years to >9.0% 
in patients aged ≥80 years.2 Because of the high prevalence 
of this rhythm disorder in the elderly population as well as 
similar risk factors for AF and severe degenerative aortic ste-
nosis, both conditions may coexist in ≤50% of patients.3,4 AF 
importantly affects cardiovascular physiology attributable to 
loss of atrioventricular synchrony and irregularity of ven-
tricular contraction resulting in reduced cardiac output and 
increased filling pressures,5 which may be further accentu-
ated in the presence of severe aortic stenosis and myocardial 
hypertrophy. Conversely, left ventricular outflow obstruction 
attributable to aortic stenosis results in left ventricular hyper-
trophy and diastolic dysfunction, which itself may precipitate 
AF attributable to increased left atrial pressures.
AF has an important impact on cardiovascular morbidity 
and mortality. Population-based studies indicate an increased 
risk of stroke and systemic embolism as well as impaired 
long-term survival of individuals with AF compared with 
those with normal sinus rhythm.6,7 Among patients with 
severe aortic stenosis and reduced left ventricular function 
undergoing surgical aortic valve replacement (SAVR), AF has 
been associated with an increased risk of perioperative and 
long-term adverse events.8 Moreover, AF is an independent 
predictor for late adverse cardiac and cerebrovascular events, 
including congestive heart failure, stroke, and mortality after 
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SAVR.9 Transcatheter aortic valve implantation (TAVI) has 
become the treatment of choice among inoperable patients 
with severe, symptomatic aortic stenosis and is a treatment 
alternative to SAVR among high-risk elderly patients. 
However, little is known regarding the impact of preexisting 
and new-onset AF among those patients undergoing TAVI for 
treatment of severe aortic stenosis. We, therefore, compared 
the long-term clinical outcomes between patients with and 
without AF undergoing TAVI enrolled in a single center 
prospective registry and followed through 1 year.
Methods
Patient Population
Between August 2007 and October 2011, a total of 389 high-risk el-
derly patients with symptomatic severe aortic stenosis were included 
in a prospective single center registry (Bern TAVI Registry). Patients 
underwent TAVI with the self-expandable Medtronic CoreValve 
(Medtronic, Minneapolis, MN) and the balloon-expandable Edwards 
Sapien transcatheter heart valve (Edwards LifeSciences, Irvine, CA) 
via the transfemoral, the transapical, and the subclavian access routes, 
as previously described.10 After the procedure, patients were either 
admitted to the intensive care or coronary care unit and monitored 
during the first 48 hours after the intervention for rhythm disturbanc-
es and other adverse events. After this, patients were transferred to 
the general ward, and rhythm disturbances were recorded with con-
tinuous monitoring using telemetric ECG surveillance. All patients 
were treated with acetylsalicylic acid 100 mg per day indefinitely and 
clopidogrel 75 mg per day for 6 months. Among patients with an indi-
cation for oral anticoagulation, a vitamin K antagonist was combined 
with either acetylsalicylic acid or clopidogrel alone.
The study complied with the Declaration of Helsinki, and the regis-
try was approved by the local ethics committee. All patients provided 
written informed consent to participate in the registry with prospec-
tive follow-up assessment.
Data Collection
All patients were evaluated for the presence and absence of AF, in-
cluding a systematic review of all electrocardiograms at the time of 
admission, during the hospitalization and at discharge. Moreover, any 
new episode of AF, irrespective of the requirement of a therapeutic in-
tervention or early spontaneous conversion into normal sinus rhythm, 
during the hospitalization was recorded. Because atrial flutter is an-
other supraventricular rhythm that may coexist or precede AF, we as-
signed patients with atrial flutter to the AF study group.
Adverse events were assessed in hospital, and regular clinical 
follow-up was performed for 30 days and 12 months by means of a 
clinical in-hospital visit or a standardized telephone interview. All sus-
pected events were adjudicated by an unblinded clinical event com-
mittee consisting of interventional cardiologists and cardiac surgeons.
Definitions
For the purpose of this study, patients were categorized into 2 groups: 
(1) patients with AF specified according to the American College of 
Cardiology Foundation/American Heart Association/Heart Rhythm 
Society classification11—paroxysmal (recurrent episodes of AF that 
terminate spontaneously within 7 days), persistent (recurrent epi-
sodes with a duration of >7 days), and permanent AF (ongoing long-
term episode) or new-onset AF after the TAVI intervention; and (2) 
patients without AF. CHADS2 scores and CHA2DS2–VASC scores 
were calculated for patients with AF.
Clinical adverse events were adjudicated according to the Valve 
Academic Research Consortium (VARC) end point definitions, de-
scribed in detail elsewhere.12 The prespecified primary end point of 
the study was all-cause mortality.
Statistical Analysis
Baseline clinical and procedural characteristics, as well as follow-
up data, were entered into a dedicated database, held at an aca-
demic clinical trials unit (Cardiobase, CTU Bern, Bern University 
Hospital) responsible for central data audits and maintenance of 
the database. Statistical analyses were performed by a statisti-
cian of an academic clinical trials unit (D.H., P.J.) using Stata 12 
(StataCorp LP, College Station, TX). Continuous variables are pre-
sented as mean±SD and are compared by means of unpaired t tests. 
Categorical data are expressed as frequencies and percentages and 
are compared using χ2 and Fisher exact tests. Survival estimates 
were reconstructed using the Kaplan–Meier method at 12-month 
follow-up. Outcomes in the AF group (raw counts [%]) were com-
pared using Cox regression analysis censoring at last follow-up 
or death, respectively (crude). The corresponding hazard ratios 
(HR, 95% confidence interval [CI]) with probability values are 
also given. The proportional hazards assumption was tested using 
Schoenfeld residuals. Endpoints with zero events were presented 
with continuity corrected risk ratios (and 95% CI), but no attempt 
was made to estimate risk ratio comparing 1 event versus 0 event. 
The adjusted Cox regression analyses (inverse probability of treat-
ment weight [IPTW]) of end points at 12 months were performed by 
weighing each patient’s effect with the IPTW, where the treatment 
is AF (coded yes=1 and no AF=0). The propensity score was cal-
culated by including all baseline characteristics affecting AF with 
a P value of <0.2 or affecting overall death at 12 months with a P 
value of <0.2. Bleeding events up to 12-month follow-up compar-
ing AF groups were analyzed using Poisson regression with robust 
error variances and reported as counts (%) with risk ratio (95% CI). 
We prespecified crude analyses comparing the different types of AF 
versus no AF. We prespecified stratified outcome IPTW analyses, 
comparing the group of patients with AF with those without AF 
according to age (cutoff point 80 years of age), sex, diabetes mel-
litus, renal failure (cutoff point glomerular filtration rate <60 mL/
min per 1.73 m2), and ejection fraction (cutoff point left ventricular 
ejection fraction, 40%). In this stratified analysis, we tested for the 
difference between patients with AF and without AF in each sub-
group separately (eg, EF <40 and >40), and we tested whether the 
interaction between the subgroup and the AF group was significant 
WHAT IS KNOWN
•	Atrial fibrillation is the most frequent arrhythmia 
and its prevalence increases with age.
•	Because of similar risk factors, atrial fibrillation and 
degenerative aortic stenosis may coexist in ≤50% of 
patients. 
•	Atrial fibrillation has an important impact on cardio-
vascular morbidity and mortality and is an indepen-
dent predictor for adverse cardiac and cerebrovascu-
lar events after surgical aortic valve replacement.
WHAT THE STUDy ADDS
•	Atrial fibrillation is observed in up to one third of 
high-risk patients with symptomatic, severe aor-
tic stenosis undergoing transcatheter aortic valve 
implantation.
•	Atrial fibrillation is associated with a 2-fold in-
creased risk of all-cause and cardiovascular mortal-
ity among patients undergoing transcatheter aortic 
valve implantation at 1-year follow-up.
•	Among patients with atrial fibrillation and severe 
aortic stenosis undergoing transcatheter aortic valve 
implantation, the CHA2DS2–VASC score directly 
correlates with the risk of all-cause mortality.
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in the model containing both subgroups (eg, EF group × AF group 
interaction). All P values and CIs are 2-sided. A P value <0.05 was 
considered statistically significant. The authors had full access to 
and take full responsibility for the integrity of the data. All authors 
have read and agree to the article as written.
Results
Patient Population
Among 389 consecutive patients undergoing TAVI for 
treatment of degenerative aortic valve stenosis, AF was 
recorded in 131 patients (33.7%). The mean CHA2DS2–
VASC score amounted to 4.5±1.2 with 96% of patients 
with AF having a score >3. AF was documented before 
the procedure (preexisting) in 104 patients (26.7%) and 
was classified as paroxysmal in 26 (25.0%), persistent in 8 
(7.7%), and permanent in 70 (67.3%) patients. New-onset AF 
was observed in 27 patients (6.9%) within 11±6 days after 
TAVI. Baseline clinical characteristics of patients undergoing 
TAVI are summarized in Table 1. Previous revascularization 
procedures were less common among TAVI patients with AF 
compared with patients without AF (coronary artery bypass 
grafting: 12% versus 22%; P=0.03; percutaneous coronary 
intervention: 18% versus 28%; P=0.03). Antithrombotic 
treatment more frequently included oral anticoagulation with 
a vitamin K antagonist among TAVI patients with (52%) than 
without AF (15%; P<0.001).
Procedural Results
Procedural characteristics and results are shown in Table 
2. The preferred treatment strategy was the transfemoral 
access route (79%), and patients were treated either with the 
Medtronic CoreValve (58%) or the Edwards Sapien (42%) 
transcatheter heart valve prosthesis. There was no significant 
difference for any of the procedural characteristics, includ-
ing procedure time, type of anesthesia, access route, and 
revascularization strategy among TAVI patients with and 
without AF.
Clinical Outcomes
Clinical outcomes through 1 year are summarized in Table 
3. All-cause mortality was higher among patients with AF 
(30.9%) compared with those without AF (13.9%; HR, 2.36; 
95% CI, 1.43–3.90; P=0.0008), which was mainly attributable 
to a higher cardiac mortality (23.4% versus 9.7%; HR, 2.37; 
95% CI, 1.32–4.26; P=0.004). The composite of all-cause 
death, major stroke, or myocardial infarction was more com-
mon among patients with AF (32.2%) than without AF (18.6%; 
HR, 1.80; 95% CI, 1.14–2.85; P=0.01), whereas there were no 
differences with respect to myocardial infarction (1.5% versus 
1.5%; HR, 1.53; 95% CI, 0.26–9.19; P=0.64), major stroke 
(3.9% versus 5.1%; HR, 0.67; 95% CI, 0.23–1.96; P=0.47), or 
transient ischemic attack (0% versus 0.6%).
The increased risk of death among patients with AF as 
compared with those without AF was more pronounced for 
preexisting (HR, 2.50; 95% CI, 1.48–4.23; P=0.00061) than 
for new-onset AF (HR, 1.91; 95% CI, 0.78–4.68; P=0.16) at 1 
year (Table I in the online-only Data Supplement) (Figure 1). 
All-cause mortality was increased for any type of AF includ-
ing permanent (HR, 2.47; 95% CI, 1.40–4.38; P=0.002), 
persistent (HR, 3.60; 95% CI, 1.10–11.78; P=0.034), and 
paroxysmal AF (HR, 2.88; 95% CI, 1.37–6.05; P=0.005) 
(Figure 2). In stratified analyses, the increased mortality risk 
among patients with AF as compared with those without AF 
was consistent across major subgroups, including age, diabe-
tes mellitus, renal function, coronary artery disease, and left 
ventricular ejection fraction (Figure 3). Among patients with 
AF, the risk of death at 1 year correlated with the CHA2DS2–
VASC score and was highest in the group of patients with a 
CHA2DS2–VASC score of >6 (HR, 4.12; 95% CI, 2.07–8.20; 
P=0.00039) (Figure 4).
Table 1. Baseline Clinical Characteristics
All Patients No AF AF P Value
N=389 N=258 N=131
Age, y 82.5±5.8 82.4±6.1 82.6±5.3 0.86
Female sex, n (%) 224 (58) 148 (57) 76 (58) 0.91
Body mass index, kg/m2 26.1±5.1 26.1±5.1 26.4±5.0 0.58
Cardiovascular risk factors
 Hypertension, n (%) 303 (78) 195 (76) 108 (82) 0.16
 Diabetes mellitus, n (%) 105 (27) 70 (27) 35 (27) 1.00
Past medical history
  Previous myocardial 
infarction, n (%)
64 (16) 47 (18) 17 (13) 0.20
 Previous CABG, n (%) 72 (19) 56 (22) 16 (12) 0.03
 Previous PCI, n (%) 94 (24) 71 (28) 23 (18) 0.03
  Previous cerebrovascular 
event, n (%)
30 (8) 19 (7) 11 (8) 0.69
Symptoms
 NYHA functional class 0.46
 NYHA I, n (%) 22 (6) 17 (7) 5 (4)
 NYHA II, n (%) 109 (28) 76 (30) 33 (25)
 NYHA III, n (%) 206 (53) 133 (52) 73 (56)
 NYHA IV, n (%) 49 (13) 30 (12) 19 (15)
Risk assessment
 Logistic EuroSCORE, % 24.3±14.2 23.7±14.2 25.4±14.1 0.26
 STS score, % 6.8±5.3 6.8±5.6 6.9±4.5 0.85
Clinical features
  Renal failure (GFR<60 mL/ 
min per 1.73 m2)
268 (69) 172 (67) 96 (73) 0.20
  Coronary artery disease, 
n (%)
238 (61) 165 (64) 73 (56) 0.12
  Left ventricular ejection 
fraction, %
51.9±14.8 52.7±15.1 50.2±14.1 0.12
 Aortic valve area, cm2 0.6±0.2 0.6±0.2 0.5±0.2 0.23
  Mean transaortic gradient, 
mm Hg
44.2±16.8 45.1±17.0 42.4±16.2 0.14
Antithrombotic therapy
 Aspirin, n (%) 237 (62) 184 (72) 53 (41) <0.001
 Clopidogrel, n (%) 69 (18) 53 (21) 16 (12) 0.0490
 Oral anticoagulation, n (%) 106 (28) 38 (15) 68 (52) <0.001
AF indicates atrial fibrillation; CABG, coronary artery bypass surgery; 
EuroSCORE, European System for Cardiac Operative Risk Evaluation; GFR, 
glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous 
coronary intervention; and STS, Society of Thoracic Surgeons.
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Antithrombotic regimen after TAVI was different in patients 
with AF compared with those without AF (Table II in the 
online-only Data Supplement). The majority of patients with-
out AF received dual antiplatelet therapy with aspirin and clop-
idogrel (84%) at the time of hospital discharge, whereas few 
patients received an individualized treatment approach with 
either vitamin K antagonist monotherapy (2%), combination 
of either aspirin and vitamin K antagonist (5%), or clopidogrel 
and vitamin K antagonist (4%). Patients with AF received dual 
antiplatelet therapy in 31%, a combination of clopidogrel and 
vitamin K antagonist in 19%, aspirin and vitamin K antagonist 
in 20%, or vitamin K antagonist monotherapy in 14% of cases 
at the time of hospital discharge. The differences in antithrom-
botic treatment between patients with AF and without AF were 
sustained at 30 days and 1 year of follow-up (P<0.001).
Discussion
The present study investigating clinical outcomes of patients 
with symptomatic severe aortic stenosis and concomitant AF 
undergoing TAVI has the following main findings:
•	 AF is common among high-risk elderly patients with symp-
tomatic severe aortic stenosis undergoing TAVI.
•	 AF is associated with a >2-fold increased risk of all-cause and 
cardiovascular mortality at 1 year in this patient population.
•	 AF confers an increased risk of mortality irrespective of type 
of AF among TAVI patients.
•	 The CHA2DS2–VASC score among patients with AF and 
severe aortic stenosis undergoing TAVI directly correlates with 
the risk of death.
The prevalence of AF in patients with symptomatic severe 
aortic stenosis is high and amounted to 34% in this elderly 
patient population. AF may be the direct result of heart 
failure precipitated by aortic stenosis attributable to increased 
atrial pressures and atrial dilatation leading to atrial fibrosis 
and regional conduction abnormalities which beget AF. 
Conversely, AF may impair symptoms of heart failure among 
patients with severe aortic stenosis attributable to loss of 
atrioventricular synchrony, the fast and irregular ventricular 
response, and sympathetic activation leading to therapeutic 
intervention. In the PARTNER (Placement of Aortic 
Transcatheter Valve) cohort B comparing TAVI with medical 
treatment among inoperable patients, the prevalence of AF 
was as high as 48.8% (TAVI group 32.9%, medical group 
48.8%),13 whereas in the PARTNER A cohort comparing TAVI 
with SAVR among high-risk surgical patients, AF was present 
in up to 42.7% of patients (TAVI group 40.8%, SAVR group 
42.7%).14 Compared with SAVR, the prevalence of new-onset 
AF in patients undergoing TAVI is lower (PARTNER A: TAVI 
8.6% versus SAVR 16%; P=0.006), the duration shorter and 
limited,15 and the pathophysiological mechanisms different. 
Although inflammatory components are responsible for 
the occurrence of new-onset AF after cardiac surgery,16 the 
mechanisms leading to the arrhythmia after minimal-invasive 
Table 2. Procedural Characteristics




Procedure time, min 82.7±35.4 82.3±34.5 83.4±37.1 0.85
Amount of contrast, mL 252.2±96.7 255.8±96.5 245.3±96.9 0.18
General anesthesia, n (%) 164 (42) 106 (41) 58 (44) 0.43
Access route 0.46
 Femoral, n (%) 308 (79) 211 (82) 97 (74)
 Apical, n (%) 76 (20) 45 (17) 31 (24)
 Subclavian, n (%) 5 (1) 2 (1) 3 (2)
Valve type 0.62
 Edwards Sapien valve, n (%) 165 (42) 104 (40) 61 (47)
 Medtronic CoreValve, n (%) 224 (58) 154 (60) 70 (53)
Revascularization
 Concomitant PCI, n (%) 63 (16) 39 (15) 24 (18) 0.27
 Staged PCI, n (%) 35 (9) 24 (9) 11 (8) 1.00
AF indicates atrial fibrillation; and PCI, percutaneous coronary intervention.
Table 3. Clinical Outcomes at 12 Months
12 mo HR or RR (95% CI) AF vs No AF P Value
Overall (n=389) No AF (n=258) AF (n=131) Crude IPTW Crude IPTW
All-cause death, n (%) 66 (19.6) 31 (13.9) 35 (30.9) 2.45 (1.51–3.98) 2.36 (1.43–3.90) 0.0003 0.0008
Cardiac events
 Cardiac death, n (%) 48 (14.2) 22 (9.7) 26 (23.4) 2.53 (1.44–4.47) 2.37 (1.32–4.26) 0.001 0.004
 Myocardial infarction, n (%) 5 (1.6) 3 (1.5) 2 (1.5) 1.42 (0.24–8.52) 1.53 (0.26–9.19) 0.70 0.64
Neurological events
 Stroke, n (%) 17 (4.8) 12 (5.1) 5 (3.9) 0.85 (0.30–2.40) 0.67 (0.23–1.96) 0.75 0.47
 Transient ischemic attack, n (%) 1 (0.4) 1 (0.6) 0 (0.0) na na na na
Bleeding events
 Life-threatening bleeding, n (%) 64 (16.5) 38 (14.7) 26 (19.8) 1.35 (0.86–2.12) 1.37 (0.86–2.19) 0.20 0.19
 Major bleeding, n (%) 125 (32.1) 85 (32.9) 40 (30.5) 0.93 (0.68–1.27) 1.02 (0.74–1.40) 0.63 0.92
Composite outcomes
 All-cause death or stroke, n (%) 77 (22.6) 40 (17.7) 37 (32.6) 1.98 (1.27–3.10) 1.89 (1.19–3.00) 0.003 0.01
AF indicates atrial fibrillation; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weight; na, not available; and RR, risk ratio. HR from Cox 
regression for crude and adjusted analyses: for all-cause death, cardiac death, myocardial infarction, major stroke, and composites. RR from Poisson regression with 
robust error variances for crude and adjusted analyses: for bleeding events. IPTW adjusted, where the treatment is AF.
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catheter-based aortic valve implantation are less well 
understood. Amat-Santos et al17 investigated the impact of 
new-onset AF among 138 high-risk patients without a history 
of previous AF undergoing TAVI and, therefore, excluded a 
priori patients with preexisting AF. In this study, new-onset 
AF was observed in up to one third of patients as compared 
with 7% in the present study and was associated with a higher 
rate of cerebrovascular events, but not death, during the 
follow-up period.
In the general population, AF is estimated to increase 
the risk of death 1.5-fold among men and 1.9-fold among 
women.6,18 Among patients with heart failure and reduced left 
ventricular function, new-onset AF has been identified as an 
independent predictor of mortality and long-term follow-up 
of the Framingham cohort, suggesting that patients with AF 
have a deleterious outcome.19 In the present study of elderly 
patients undergoing TAVI, patients with AF experienced 
worse clinical outcome with respect to all-cause death and 
cardiovascular mortality compared with patients without 
AF. These findings are supported by a recent multicenter 
study evaluating prognostic factors and long-term outcomes 
after TAVI. In this study, chronic AF emerged as 1 of the 
predictors of late mortality with a 1.4-fold increased risk 
for all-cause mortality.20 This observation among patients 
undergoing TAVI is in accordance with outcomes after SAVR 
in patients with preexisting AF and reduced left ventricular 
function, where AF is associated with an ≈8-fold increased 
risk of mortality8 compared with patients without AF during 
short- and long-term follow-up.9 Multiple reasons might be 
responsible for this. In most cases, the development of AF 
is an expression of advanced heart disease with structural 
remodeling and myocardial fibrosis,21 which by accelerating 
the process of cardiac senescence may increase cardiovascular 
mortality. Moreover, the loss of atrioventricular synchrony 
and the variation in ventricular cycle length lead to 
impaired ventricular filling, reduced cardiac output, and 
increased afterload, which are hemodynamic factors known 
to adversely affect clinical outcomes among heart failure 
patients. Of note, we did not observe differences in rates 
of stroke or systemic embolism between patients with and 
without AF in the present study as potential explanation for 
differences in mortality. Although we cannot exclude the 
Figure 1. Cumulative incidence of all-cause mor-
tality among patients with preexisting, new-onset 
atrial fibrillation (AF), and patients without AF dur-
ing the follow-up period of 12 months. CI indicates 
confidence interval; HR, hazard ratio; and TAVI, 
transcatheter aortic valve implantation.
Figure 2. Stratified analysis according to type of atrial fibrillation (AF) for all-cause mortality at 12 months. CI indicates confidence 
interval.
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benefit of appropriately chosen antithrombotic therapy, it is 
more likely that the majority of strokes occurred during the 
peri-interventional period and, therefore, represented adverse 
events related to the procedure potentially camouflaging the 
risk of stroke inherent to AF.22
Patients with AF experienced an increased risk of death 
irrespective of the type of AF, including permanent (HR, 2.47; 
95% CI, 1.40–4.38; P=0.002), persistent (HR, 3.60; 95% CI, 
1.10–11.78; P=0.034), and paroxysmal AF (HR, 2.88; 95% 
CI, 1.37–6.05; P=0.005) in the present study. The European 
Heart Survey on AF observed the highest rate of death among 
patients with permanent AF, although mortality remained sub-
stantial among patients with first onset of AF.23 In the French 
Etude en Activité Libérale de la Fibrillation Auriculaire 
(ALFA) study, the type of AF was not predictive of mortality 
and risk of systemic embolism. Similarly, the risk of stroke 
has been shown as high for paroxysmal as for persistent and 
permanent AF in previous cohort studies.24
AF constitutes a major risk factor for cardioembolic isch-
emic events that are associated with significant disability, 
partial or total loss of independence in everyday life activi-
ties, and a high rate of mortality.22 The recommended anti-
thrombotic therapy is able to reduce these events, while 
increasing the risk for bleeding especially in this elderly 
patient population.25 The CHADS2- and more recently the 
CHA2DS2–VASC score provide a reliable risk stratification 
Figure 3. Stratified analysis for all-cause mortality among major subgroups. CI indicates confidence interval; GFR, glomerular filtration 
rate; and IPTW, inverse probability of treatment weight.
Figure 4. Cumulative incidence of all-cause mor-
tality among patients with atrial fibrillation (AF) 
compared with patients without AF according to 
the CHA2DS2–VASC risk stratification. CI indicates 
confidence interval; HR, hazard ratio; and TAVI, 
transcatheter aortic valve implantation.
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for cerebrovascular events in patients with AF.26 The 
CHA2DS2–VASC score was a marker of impaired prognosis 
in the present study with a gradual increase in the risk of 
death with increasing CHA2DS2–VASC scores (Figure 4). 
The predictive ability of the CHA2DS2–VASC score in terms 
of death in patients with AF has been recently confirmed in 
a large patient population from the Prospective Danish Diet, 
Cancer and Health cohort study.27
Limitations
Several limitations need to be acknowledged, when interpret-
ing the results of this study. First, the study population is based 
on the experience of a single, tertiary care center, and the 
results may not be applicable to other centers with different 
procedural experience, as well as device and patient selection. 
Second, the assessment of AF was based on preprocedural 
ECG evaluation and the review of patient charts, including 
past medical history as well as previous reports from refer-
ring cardiologists and general practitioners. Despite careful 
and complete assessment of patient data, only symptomatic 
and apparent episodes of AF have been detected, leaving a 
small proportion of patients with asymptomatic, paroxysmal 
AF which may have been undetected. Finally, because of the 
preprocedural evaluation algorithm at our institution to per-
form transesophageal echocardiography rather than transtho-
racic echocardiography, we are unable to include reliable data 
on left atrial size, myocardial mass, or other specific hemody-
namic data in our analysis.
Conclusion
AF is common among high-risk patients with severe aor-
tic stenosis undergoing TAVI and is associated with a >2-fold 
increased risk of all-cause and cardiovascular mortality, irre-
spective of the type of AF. The gradient of risk directly cor-
relates with the CHA2DS2–VASC score.
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Supplemental Table 1   Clinical Outcomes at 12 Months           
         
    12 Months  Baseline AF vs No AF New-Onset AF vs No AF  Overall p-value 
  No AF Baseline AF 
New-
Onset AF  Crude IPTW  Crude IPTW  Crude IPTW 
  n=258 n=104 n=27                
All Cause Death, n(%) 31(13.9%) 29(32.2%) 6(25.8%)  2.64(1.59-4.38) 2.50(1.48-4.23)  1.84(0.77-4.41) 1.91(0.78-4.68)  0.0009 0.0025 
Cardiac Events                      
  Cardiac Death, n(%) 22(9.7%) 23(26.0%) 3(13.3%)  2.89(1.61-5.20) 2.72(1.49-4.97)  1.30(0.39-4.34) 1.22(0.36-4.14)  0.0016 0.0045 
  Myocardial Infarction, n(%) 3(1.5%) 1(1.0%) 1(3.7%)  0.91(0.09-8.78) 1.26(0.14-11.54)  3.21(0.33-30.87) 2.49(0.25-24.37)  0.57 0.74 
                       
Neurologic Events                      
  Stroke, n(%) 12(5.1%) 5(4.9%) 0(0.0%)  1.08(0.38-3.07) 0.87(0.30-2.51)  0.003(0->99)* na  0.78* na 
  Transient Ischemic Attack, n(%) 1(0.6%) 0(0.0%) 0(0.0%)  na na na na  na na 
                       
Bleeding Events                      
  Life Threatening Bleeding, n(%) 38(14.7%) 17(16.3%) 9(33.3%)  1.11(0.66-1.88) 1.16(0.68-2.00)  2.26(1.23-4.16) 2.13(1.11-4.07)  0.0301 0.0728 
  Major Bleeding, n(%) 85(32.9%) 30(28.8%) 10(37.0%)  0.88(0.62-1.24) 0.99(0.70-1.41)  1.12(0.67-1.90) 1.11(0.63-1.94)  0.64 0.93 
                       
Composite Outcomes                      
  All Cause Death or Stroke, n(%) 40(17.7%) 31(34.2%) 6(25.8%)  2.16(1.35-3.46) 2.02(1.24-3.30)  1.39(0.59-3.28) 1.45(0.61-3.48)  0.0056 0.0182 
                       
Hazard ratios HR from Cox's regression: for all-cause death, cardiac death, MI, major stroke and composites        
Relative risk ratios RR from Poisson regression with robust error variances: for bleeding events          
Index: RR with continuity correction (adding 1/n of opposite treatment group), p-value from Fisher's exact test            
  
Supplemental Table 2   Antithrombotic Regimen According to Atrial Fibrillation 
    
  No AF AF p-value 
  
  N = 258 N = 131   
        
Discharge     <0.001 
Aspirin Single Therapy, n (%) 5 (2%) 5 (4%)   
Clopidogrel Single Therapy, n (%) 4 (2%) 4 (3%)   
Warfarin Single Therapy, n (%) 6 (2%) 17 (14%)   
Aspirin + Clopidogrel, n (%) 209 (84%) 37 (31%)   
Aspirin + Warfarin, n (%) 13 (5%) 24 (20%)   
Clopidogrel + Warfarin, n (%) 9 (4%) 23 (19%)   
Aspirin + Clopidogrel + Warfarin, n (%) 2 (1%) 9 (8%)   
30 Days Follow Up     <0.001 
Aspirin Single Therapy, n (%) 23 (10%) 11 (10%)   
Clopidogrel Single Therapy, n (%) 10 (4%) 4 (4%)   
Warfarin Single Therapy, n (%) 7 (3%) 22 (20%)   
Aspirin + Clopidogrel, n (%) 173 (73%) 38 (34%)   
Aspirin + Warfarin, n (%) 14 (6%) 15 (14%)   
Clopidogrel + Warfarin, n (%) 4 (2%) 17 (15%)   
Aspirin + Clopidogrel + Warfarin, n (%) 7 (3%) 4 (4%)   
12 Months Follow Up     <0.001 
Aspirin Single Therapy, n (%) 78 (49%) 12 (21%)   
Clopidogrel Single Therapy, n (%) 6 (4%) 6 (11%)   
Warfarin Single Therapy, n (%) 15 (9%) 23 (40%)   
Aspirin + Clopidogrel, n (%) 47 (29%) 7 (12%)   
Aspirin + Warfarin, n (%) 12 (8%) 6 (11%)   
Clopidogrel + Warfarin, n (%) 2 (1%) 3 (5%)   
Aspirin + Clopidogrel + Warfarin, n (%) 0 (0%) 0 (0%)   
        
        
 
 
